UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $86.00 | Equal Weight | Barclays |
| 10/7/2025 | $83.00 | Buy → Neutral | Citigroup |
| 5/5/2025 | $73.00 | Sell → Neutral | UBS |
| 3/11/2025 | $85.00 → $100.00 | Neutral → Buy | Goldman |
| 1/8/2025 | $95.00 → $103.00 | Hold → Buy | Jefferies |
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
NVIDIA technology is now integrated into several of GE HealthCare's new imaging solutions, including Photonova Spectra1, SIGNA Sprint with Freelium2, SIGNA Bolt3, Vivid Pioneer, and Pristina Recon DL. At RSNA 2025, GE HealthCare is also gathering feedback on early-stage exploratory workflow concepts4 within ultrasound and X-ray that incorporate autonomous technologies for continued research and development. At the Radiological Society of North America (RSNA) 2025 Annual Meeting, GE HealthCare (NASDAQ:GEHC) is showcasing several innovations brought to life through an expanded collaboration with NVIDIA. This collaboration underscores GE HealthCare's ongoing commitment to integrating adva
Compact, cable-free C-arm aims to maximize space and movement and allow greater flexibility and accessibility for everyday performance Patient-centric design featuring lateral wide-bore cone beam computed tomography with the goal of enhancing image quality to accommodate a range of patients and procedures for more inclusive care Built to empower clinicians with a future-ready environment aimed to provide enhanced efficiency and versatility, enabling improved patient outcomes GE HealthCare (NASDAQ:GEHC) today unveiled the Allia™ Moveoi, an image guiding solution designed to enhance mobility and flexibility and redefine the way clinicians deliver care in the interventional suite. This
The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions. GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precision care. At this year's Radiological Society of North America's (RSNA) 2025 Annual Meeting, GE HealthCare (NASDAQ:GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersec
Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00
Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)
144 - GE HealthCare Technologies Inc. (0001932393) (Subject)
BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob
GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for mo
Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical te
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)